Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2004-04-14

Last Posted Date: 2020-04-01

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 224

Registration Number: NCT00003032

Locations: 🇨🇦
Humber River Regional Hospital, Weston, Ontario, Canada
🇨🇦
Centre Hospitalier Universitaire de Quebec, Pavillion de Quebec, Quebec City, Quebec, Canada
🇨🇦
William Osler Health Centre, Brampton, Ontario, Canada

and more 22 locations

Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer

Phase 2

Conditions: Breast Cancer

First Posted Date: 2004-04-13

Last Posted Date: 2014-01-06

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Registration Number: NCT00012311

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center, New York, New York, United States

Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers

Phase 2

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2004-04-09

Last Posted Date: 2013-06-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00003754

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

Phase 1

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

First Posted Date: 2004-04-08

Last Posted Date: 2012-03-08

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 20

Registration Number: NCT00080925

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

Phase 2

Withdrawn

Conditions: Myelodysplastic Syndromes
Graft Versus Host Disease
Leukemia

First Posted Date: 2004-04-08

Last Posted Date: 2014-12-04

Lead Sponsor: Mesoblast International Sàrl

Registration Number: NCT00081055

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Stage III Adult Diffuse Large Cell Lymphoma
Stage IV Adult Diffuse Large Cell Lymphoma

Interventions: Biological: rituximab
Biological: oblimersen sodium
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: prednisone
Other: laboratory biomarker analysis

First Posted Date: 2004-04-08

Last Posted Date: 2013-01-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 160

Registration Number: NCT00080847

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's Disease

Phase 3

Conditions: Lymphoma

First Posted Date: 2004-04-06

Last Posted Date: 2013-12-04

Lead Sponsor: Medical Research Council

Target Recruit Count: 400

Registration Number: NCT00002987

Locations: 🇿🇦
Groote Schuur Hospital, Cape Town, Cape Town, South Africa
🇬🇧
Royal Preston Hospital, Preston, United Kingdom
🇬🇧
Bristol Royal Hospital for Sick Children, Bristol, England, United Kingdom

and more 15 locations

Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2004-04-06

Last Posted Date: 2013-11-06

Lead Sponsor: Scottish Cancer Therapy Network

Target Recruit Count: 1000

Registration Number: NCT00003012

Locations: 🇬🇧
Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom
🇬🇧
Royal Alexandra Hospital, Paisley, Scotland, United Kingdom
🇬🇧
Western General Hospital, Edinburgh, Scotland, United Kingdom

and more 7 locations

Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

Phase 1

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2004-04-06

Last Posted Date: 2019-02-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 23

Registration Number: NCT00002600

Locations: 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: leucovorin calcium
Drug: mesna
Drug: methotrexate
Drug: prednisone
Drug: therapeutic hydrocortisone
Drug: vincristine sulfate
Radiation: low-LET cobalt-60 gamma ray therapy
Radiation: low-LET photon therapy

First Posted Date: 2004-04-06

Last Posted Date: 2016-07-04

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 134

Registration Number: NCT00002494

Locations: 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸
University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
🇺🇸
Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States

and more 20 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy